Namenda
Brand names,
Namenda
Analogs
Namenda
Brand Names Mixture
Namenda
Chemical_Formula
C12H21N
Namenda
RX_link
http://www.rxlist.com/cgi/generic3/namenda.htm
Namenda
fda sheet
Namenda
msds (material safety sheet)
Namenda
Synthesis Reference
No information avaliable
Namenda
Molecular Weight
179.302 g/mol
Namenda
Melting Point
258 oC (HCl salt)
Namenda
H2O Solubility
35 mg/mL (HCl salt), 0.9 mg/mL for free base
Namenda
State
Solid
Namenda
LogP
2.197
Namenda
Dosage Forms
Tablet
Namenda
Indication
For the treatment of moderate to severe dementia of the Alzheimer's type.
Namenda
Pharmacology
Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer's disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.
Namenda
Absorption
Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
Namenda
side effects and Toxicity
Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
Namenda
Patient Information
Information for Patients and Caregivers: Caregivers should be instructed in the recommended administration
(twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).
Namenda
Organisms Affected
Humans and other mammals